Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
  • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/14—Decongestants or antiallergics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents

Definitions

• the present invention relates to adenine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
• the immune system is comprised of innate and acquired immunity, both of which work cooperatively to protect the host from microbial infections. It has been shown that innate immunity can recognize conserved pathogen-associated molecular patterns through toll- like receptors (TLRs) expressed on the cell surface of immune cells. Recognition of invading pathogens then triggers cytokine production (including interferon alpha(IFN ⁇ )) and upregulation of co-stimulatory molecules on phagocytes, leading to modulation of T cell function.
• TLRs toll- like receptors
• TLRs are a family of type I transmembrane receptors characterized by an NH 2 -terminal extracellular leucine-rich repeat domain (LRR) and a COOH-terminal intracellular tail containing a conserved region called the ToU/IL-1 receptor (TIR) homology domain.
• LRR extracellular leucine-rich repeat domain
• TIR ToU/IL-1 receptor
• the extracellular domain contains a varying number of LRR, which are thought to be involved in ligand binding.
• TLRs have been described to date in humans and mice. They differ from each other in ligand specificities, expression patterns, and in the target genes they can induce.
• TLRs also known as immune response modifiers (IRMS)
• IRMS immune response modifiers
• R , 1 represents hydrogen, hydroxyl, Ci-C 6 alkoxy, C 2 -C 5 alkoxycarbonyl, or a C 6 - Ci 0 aryl, C 5 -Ci 0 heteroaryl or C 3 -C 8 cycloalkyl group, wherein any available carbon atom in each group is optionally substituted by one or more substituents independently selected from halogen, hydroxyl, Ci-C 6 alky 1, Ci-C 6 haloalkyl, Ci-C 6 alkoxy, Cj-C 6 haloalkoxy, C 2 -C 5 alkoxycarbonyl, amino, mono or di-Ci-C 6 alkylamino;
• Y 1 represents a single bond or C]-C 6 alkylene
• X 1 represents a single bond or an oxygen or sulphur atom , sulphinyl (SO), sulphonyl (SO 2 ) or NR 4 where R 4 is hydrogen or Ci -6 alkyl; provided that when R 1 is hydroxyl, Ci -6 alkoxy or C 2 -C 5 alkoxycarbonyl and X 1 is oxygen, Y 1 is other than a single bond;
• L is a bond or a straight or branched Ci -6 alkylene group, wherein up to 3 carbon atoms within the alkylene group may be replaced by oxygen, sulfur, SO, SO 2 , carbonyl or NR 5 wherein R 5 is hydrogen or Ci -6 alkyl;
• R 2 is either a saturated or partially unsaturated 4-8 membered heterocycle comprising 1 or 2 hetero atoms selected from nitrogen, oxygen and sulphur, provided that at least one of the heteroatoms is nitrogen, which heterocycle is optionally substituted by one or more groups selected from halogen, hydroxyl, oxo, Ci -6 alkoxy, C 2-6 alkylcarbonyl, Ci -6 alkylsulfonyl, carbamoyl, Ci -6 alkylcarbamoyl, di-Ci -6 alkylcarbamoyl, Ci -6 alkylsulfinyl or an Ci -6 alkyl group wherein from 1 to 3 carbon atoms are optionally replaced by oxygen, sulphur, SO, SO 2 , carbonyl or a group NR 3 where R 3 is hydrogen or Ci -6 alkyl; or R 2 is a group of sub formula (i) (i)
• R 6 is hydrogen or Ci -6 alkyl
• R 7 is hydrogen, or Ci -6 alkyl
• R 8 is hydrogen, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, a C 6 -Ci 0 aryl, C 5 -Ci O heteroaryl, C 3 -C 8 cycloalkyl or a 3-8 membered saturated or partially saturated heterocyclic ring wherein each group may be optionally substituted by one or more groups selected from halogen, cyano, S(O) m R 10 , OR 10 , C(O)R 10 , CO 2 R 10 , OC(O)R 10 , SO 2 NR 11 R 12 , CONR 11 R 12 , NR 11 R 12 , NR 11 SO 2 R 10 , NR 11 CO 2 R 10 , NR 11 COR 10 , where any CpC 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C 3 -C 8 cycloalkyl groups R 8 may also be optionally
• R 9 is hydrogen, S(O) m R 16 , C(O)R 16 , SO 2 NR 17 R 18 , CONR 17 R 18 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C 3 -C 8 cycloalkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, cyano, S(O) m R 19 , OR 19 , C(O)R 19 , OC(O)R 19 , CO 2 R 19 , SO 2 NR 20 R 21 , CONR 20 R 21 , NR 20 R 21 , NR 20 SO 2 R 19 , NR 20 CO 2 R 19 or NR 20 COR 19 ; where m is 0, 1 or 2, provided that when R 8 is a C 6 -C 10 aryl or a C 5 -Ci 0 heteroaryl, R 9 is not hydrogen or unsubstituted Ci-C 6
• an alkyl substituent group or an alkyl moiety in a substituent group may be linear or branched. They may for example contain from 1 to 6 carbon atoms.
• C 1 -C 6 alkyl groups/moieties include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl and n- hexyl.
• an alkylene group/moiety may be linear or branched.
• Examples OfC 1 -C 6 alkylene groups/moieties include methylene, ethylene, n-propylene, n-butylene, n- pentylene, n-hexylene, 1-methylethylene, 2-methylethylene, 1 ,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 1-, 2- or 3-methylpropylene and 1-, 2- or 3- ethylpropylene.
• An alkenyl or alkynyl group is an unsaturated linear or branched group, containing for example from 2 to 6 carbon atoms.
• Cycloalkyl or carbocycle groups are rings containing, for example, from 3 to 8 carbon atoms and are saturated.
• Heterocyclic groups are rings which may be saturated, partially unsaturated or unsaturated, and contain from 3 to 20 atoms, at least one and suitably from 1 to 4 atoms are heteroatoms selected from oxygen, sulphur and nitrogen. Rings may be monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring system(s).
• Monocyclic heterocyclic rings contain from about 3 to 12 ring atoms, with from 1 to 5 heteroatoms selected from N, O, and S, and suitably from 3 to 7 member atoms, in the ring.
• Bicyclic heterocycles contain from 7 to 17 member atoms, suitably 7 to 12 member atoms, in the ring.
• Bicyclic heterocycles contain from about 7 to about 17 ring atoms, suitably from 7 to 12 ring atoms.
• Bicyclic heterocyclic(s) rings may be fused, spiro, or bridged ring systems.
• rings which are described as being “partially unsaturated” may contain one or more multiple bonds but they are not aromatic in nature.
• heterocyclic groups which are saturated or partially saturated include cyclic ethers (oxiranes) such as ethyleneoxide, tetrahydrofuran, dioxane, and substituted cyclic ethers.
• cyclic ethers oxiranes
• Heterocycles containing nitrogen include, for example, azetidine, pyrrolidine, piperidine, piperazine, tetrahydrotriazine, tetrahydropyrazole, and the like.
• Typical sulfur containing heterocycles include tetrahydrothiophene, dihydro-l,3-dithiol-2-yl, and hexahydrothiepin-4-yl.
• heterocycles include dihydro-oxathiol-4-yl, tetrahydro-oxazolyl, tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydro-oxathiazolyl, hexahydrotriazinyl, tetrahydro-oxazinyl, morpholinyl, thiomo ⁇ holinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl.
• heterocycles containing sulfur the oxidized sulfur heterocycles containing SO or SO 2 groups are also included.
• examples include the sulfoxide and sulfone forms of tetrahydrothiophene.
• a suitable value for a heterocyclyl group which bears 1 or 2 oxo or thioxo substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl,
• heterocyclic groups which are aromatic in nature are referred to as "heteroaryl” groups. These groups are aromatic mono-, bi-, or polycyclic heterocyclic ring incorporating one or more (for example 1-4) heteroatoms selected from N, O, and S.
• heteroaryl includes both monovalent species and divalent species.
• heteroaryl groups include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl,
• Heteroaryl also covers ring systems wherein at least one ring is an aromatic ring containing 1 or more heteroatoms selected from O, S and N and one or more of the other rings is a non-aromatic, saturated or partially unsaturated ring optionally containing one or more heteroatoms selected from O, S and N, for example l,2,3,4-tetrahydro-l,8-naphthyridinyl, 1 ,2,3,4-tetrahydropyrido[2,3- ⁇ ]pyrazinyl and 3,4-dihydro-2H-pyrido[3,2-6] [1 ,4]oxazinyl.
• R 1 represents hydrogen.
• Y 1 represents unsubstituted such as a linear Ci -6 alkylene for instance methyl, ethyl, propyl, n-butyl, n-pentyl or n-hexyl.
• R 1 is n-butyl
• X 1 groups are oxygen, sulphur, or NR 4 , where R 4 is as defined above.
• suitable R 4 groups include hydrogen or methyl, and in particular hydrogen.
• X 1 represents oxygen
• any of the carbon atoms within the L group are replaced by oxygen, sulfur, SO, SO 2 , carbonyl or NR 5 , these are suitably arranged at an intermediate position in the alkylene chain so that the terminal atoms of L are carbon.
• L contains an NR 5 group
• R 5 is suitably hydrogen or Ci -6 alkyl such as hydrogen or methyl.
• up to 2 carbon atoms within the alkylene group of L may be replaced by oxygen, sulfur, SO, SO 2 , carbonyl or NR 5 .
• no more than one carbon atom within L is replaced by oxygen, sulfur, SO, 20 SO 2 , carbonyl or NR 5 .
• L is a bond or a straight or branched Ci -6 alkylene, and in particular a straight chain alkylene such as n-propylene.
• L is an alkylene chain wherein two carbon atoms are replaced, one by a carbonyl group and one by a group NR 5 .
• R 2 is a saturated or partially unsaturated 4-8 membered heterocycle comprising 1 or 2 heteroatoms selected from nitrogen, oxygen and sulphur, 30 provided that at least one of the heteroatoms is nitrogen, which may be optionally substituted as described above.
• R 2 is pyrrolidine, piperidine, piperidine, morpholine, thiomorpholine, thiomorpholine-1 -oxide or thiomorpholine-1, 1 -dioxide.
• R 2 is a saturated nitrogen containing heterocycle such as pyrrolidinyl or morpholine.
• the ring R 2 is linked to the group L by way of a ring nitrogen atom.
• the ring R 2 may be unsubstituted.
• the ring R 2 may carry one or more substituents, for example from one to three substituents independently selected from halogen, hydroxyl, oxo, Ci -6 alkoxy, C 2-6 . alkylcarbonyl, Ci -6 alkylsulfonyl, carbamoyl, Ci -6 alkylcarbamoyl, di-Ci -6 alkylcarbamoyl, Ci -6 alkylsulfinyl or a Ci -6 alkyl group wherein from 1 to 3 carbon atoms are optionally replaced by oxygen, sulphur, SO, SO 2 , carbonyl or a group NR 3 where R 3 is hydrogen or C ⁇ -6 alkyl.
• substituents for example from one to three substituents independently selected from halogen, hydroxyl, oxo, Ci -6 alkoxy, C 2-6 . alkylcarbonyl, Ci -6 alkylsulfonyl, carbamoyl, Ci -6 alkyl
• R 2 when R 2 is a ring, it is optionally substituted by one or two oxo groups.
• a further example of a suitable substituent for R 2 is an alkyl group which is optionally interposed with an oxygen atom, so as to form a alkoxyalkyl group such as a Ci- 3 alkoxyCi -2 alkyl group, for instance methoxymethyl.
• Another suitable substitutent for a ring R 2 is such as dimethy lcarbamoy 1.
• R 2 is a group of sub formula (i)
• R 6 and R 7 are independently hydrogen or C] -3 alkyl.
• R 6 is hydrogen or methyl.
• R 7 is hydrogen or methyl
• R 8 is hydrogen or Ci -6 alkyl which may be optionally substituted as defined above, such as optionally substituted methyl.
• R 8 is hydrogen or a Ci -6 alkyl optionally substituted by one or more groups selected from C 2-5 alkoxycarbonyl, carboxy, hydroxy, amino optionally substituted by one or two Ci -6 alkyl groups which may be the same or different, carbamoyl optionally substituted by one or two Ci -6 alkyl groups which may be the same or different,, 6-10 membered aryl optionally substituted by halogen, hydroxy, Ci -6 alkyl, Ci -6 alkoxy, Cj- ⁇ haloalkyl, Ci -6 haloalkoxy, or amino optionally substituted by one or two Ci -6 alkyl groups which may be the same or different.
• R 8 is a Ci -6 alkyl group substituted by Ci -6 alkoxy such as methoxy.
• R 9 include hydrogen or a CONR 17 R 18 where R 17 and R 18 are as defined above.
• R 17 and R 18 are Ci -6 alkyl groups such as methyl, or R 17 and R 18 together with the nitrogen atom to which they are attached form a a 3- to 8-membered saturated heterocyclic ring comprising a ring nitrogen atom and optionally one or more further heteroatoms independently selected from nitrogen, oxygen, sulphur and sulphonyl, such as a morpholine ring.
• Examples of compounds of the invention include: 6- Amino-2-butoxy-9-(3-pyrrolidin- 1 -ylpropyl)-7,9-dihydro-8H-purin-8-one; l-[3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl]-N,N-dimethyl-L- prolinamide; 6-Amino-2-butoxy-9- ⁇ 3-[(25)-2-(methoxymethyl)pyrrolidin-l-yl]propyl ⁇ -7,9-dihydro-8H- purin-8-one;
• the present invention further provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above which comprises reacting a compound of formula (II)
• R 2 is as defined in relation to formula (I), except that where R 2 is a substituted or unsubstituted saturated or unsaturated 4-8 membered heterocycle, it is linked to the H group of formula (III) by way of a nitrogen atom.
• Suitable leaving groups Z are halogen atoms such as bromine, or chlorine, as well as mesylate and tosylate.
• the reaction is suitably carried out in an organic solvent such as dimethylsulphoxide (DMSO), acetonitrile or ⁇ N-dimethylformamide for example, using an excess of the amine, preferably at moderate to elevated temperature, e.g. at a temperature in the range from 0 to 150°C.
• the reaction may be conducted in the presence of a base such as an alkali metal carbonate (e.g. sodium carbonate or potassium carbonate).
• a base such as an alkali metal carbonate (e.g. sodium carbonate or potassium carbonate).
• the compound of formula (B) is prepared by reacting the compound of formula (A) with ammonia in an organic solvent such as methanol, ethanol, propanol, butanol, tetrahydrofuran, 1,4-dioxane, diglyme, acetonitrile or an aqueous mixture of any one of the preceding solvents.
• the reaction may be carried out in an autoclave, and at a temperature, for example, in the range from 20 to 200°C.
• Compounds of formula (C) may be prepared by reacting the compound of formula (B) with an alkanol in the presence of a base such as sodium hydride or potassium t-butoxide and in an organic solvent such as tetrahydrofuran, 1,4-dioxane, diglyme, ⁇ N-dimethylformamide or dimethylsulfoxide, preferably at elevated temperature, e.g. at a temperature in the range 5 from 20 to 15O 0 C.
• a base such as sodium hydride or potassium t-butoxide
• organic solvent such as tetrahydrofuran, 1,4-dioxane, diglyme, ⁇ N-dimethylformamide or dimethylsulfoxide
• an alkali metal such as sodium may be dissolved in the alkanol and then reacted with the compound of formula (B), preferably at elevated temperature, e.g. at a temperature in the range from 20 to 150°C.
• Compounds of formula (D) are prepared by brominating a compound of formula (C).
• the io reaction may be carried out using a brominating agent such as bromine, hydroperbromic acid or iV-bromosuccinimide (NBS), in an organic solvent such as carbon tetrachloride, methylene chloride, dichloroethane, diethyl ether, acetic acid or carbon disulfide.
• a brominating agent such as bromine, hydroperbromic acid or iV-bromosuccinimide (NBS)
• NBS iV-bromosuccinimide
• the reaction temperature will generally be in the range from 0°C to the boiling point of the solvent.
• Compounds of formula (E) are prepared by reacting a compound of formula (D) with sodium methoxide in an organic solvent such as methanol and at a temperature, for example, in the range from 20 to 150 0 C.
• Compounds of formula (F) may be obtained by treating a compound of formula (E) with an acid such as trifluoroacetic acid in an organic solvent such as methanol.
• reaction 2 5 is a leaving group such as a halogen, mesylate or triflate.
• the reaction may be carried out in an organic solvent such as iV,N-dimethylformamide, dimethylsulfoxide or acetonitrile with a base present, preferably at room temperature (20 0 C).
• a base such as an alkali metal carbonate, e.g. sodium carbonate or potassium carbonate; an alkaline earth metal carbonate, e.g. calcium carbonate; a metal hydroxide, e.g. sodium hydroxide or potassium
• hydroxide e.g. sodium hydride
• metal alkoxide e.g. potassium t- butoxide
• Compounds of formula (II) may be obtained by treatment of a compound of formula (G) with an acid.
• the reaction may be carried out in an organic solvent such as methanol using either an inorganic acid such as hydrochloric acid, hydrobromic acid or sulfuric acid, or an organic acid such as trifluoroacetic acid.
• compounds of formula (I) may be prepared by reacting a compound of formula (IV)
• L, R 2 , R 1 , X 1 and Y 1 are as defined in relation to formula (I) and R 38 is a group such as methyl, with an acid which is either an inorganic acid such as hydrochloric acid, hydrobromic acid or sulfuric acid, or an organic acid such as trifluoroacetic acid.
• the reaction may be carried out in an organic solvent such as methanol.
• compounds of formula (I) may be prepared by reacting a compound of formula (VI)
• reaction is suitably carried out in the presence of a base, such as an alkali or alkaline earth metal carbonate or hydride, such as sodium or potassium carbonate or hydride or an organic base such as triethylamine, in particular where X 1 is an oxygen or sulphur atom.
• a base such as an alkali or alkaline earth metal carbonate or hydride, such as sodium or potassium carbonate or hydride or an organic base such as triethylamine, in particular where X 1 is an oxygen or sulphur atom.
• an organic solvent such as an alcohol such as propenol or butanol, tetrahydrofuran, dimethylformamide, dimethylsulphoxide or diglyme, at elevated temperatures for example in the range of from 50-200°C.
• Compounds of formula (I) may also be prepared by reacting a compound of formula (XI) (Xl) where R 1 , X 1 , Y 1 , L and R 2 are as defined above in relation to formula (I) using conditions similar to those described above for the conversion of a compound of formula (VIII) to a compound of formula (VI).
• Couplings of compounds (V) and (VII) can be carried out using conditions similar to those described above in relation to the reactions in which these reagents take part.
• compounds of formula (I) may be prepared by the following general scheme: NC. ,NK OCN. .Ff
• R 1 , X 1 , Y 1 , L and R 2 are as defined in relation to formula (I) and Z 2 is a leaving group, such as halogen for example chlorine.
• compounds of formula (I) may be prepared by reacting a compound of formula (XIV) with a compound of formula (XV) in the presence of a base such as an alkali or alkaline earth metal carbonate, hydroxide or hydride such as sodium or potassium carbonate, hydroxide or hydride.
• a base such as an alkali or alkaline earth metal carbonate, hydroxide or hydride such as sodium or potassium carbonate, hydroxide or hydride.
• the reaction is suitably effected in an organic solvent such as a halogenated hydrocarbon, for example carbon tetrachloride, chloroform etc. at a temperature in the range of from O 0 C to the boiling point of the solvent.
• Compounds of formula (XIV) are suitably prepared by reacting a compound of formula (XVII) with an appropriate cyclising agent.
• an appropriate cyclising agent for example, where X 1 is amino, the cyclising agent will be guanidine, where X 1 is hydroxyl, the cyclising agent is urea and where X 1 is mercapto, the cyclising agent is benzoyliothiocyanate.
• the reaction can be effected in the presence of a base such as those described above and an organic solvent such as THF etc. at temperatures conveniently in the range of from room temperature to about the boiling point of the solvent.
• compounds of formula (XVII) can be cyclised directly to compounds of formula (I) by reaction with a compound of formula (XVI).
• a reaction may be effected in the presence of a base such as alkali or alkaline earth metal carbonate, hydroxide or hydride such as sodium or potassium carbonate, hydroxide or hydride or an organic base such as triethylamine, diisopropylamine, pyridine or a metal alkoxide such as sodium methoxide.
• Organic solvents may be employed such as tetrahydrofuan or an alkyl alcohol such as methanol or ethanol. Temperatures in the range of from room temperature to the boiling point of the solvent may be used.
• reaction is suitably effected in the presence of a base such as alkali or alkaline earth metal carbonate, hydroxide or hydride such as sodium or potassium carbonate, hydroxide or hydride or an organic base such as triethylamine, diisopropylamine, pyridine or a metal alkoxide such as sodium methoxide.
• a base such as alkali or alkaline earth metal carbonate, hydroxide or hydride such as sodium or potassium carbonate, hydroxide or hydride or an organic base such as triethylamine, diisopropylamine, pyridine or a metal alkoxide such as sodium methoxide.
• Organic solvents may be employed such as tetrahydrofuan or an alkyl alcohol such as methanol or ethanol. Temperatures in the range of from 0°C to the boiling point of the solvent may be used.
• the compounds of formula (I) above may be converted to a pharmaceutically acceptable salt thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, trifluoroacetate, sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate,o pyruvate, succinate, oxalate, methanesulphonate or/>-toluenesulphonate.
• an acid addition salt such as a hydrochloride, hydrobromide, trifluoroacetate, sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate,o pyruvate, succinate, oxalate, methanesulphonate or/>-toluenesulphonate.
• the compounds of formula (I) and their pharmaceutically acceptable salts have activity as0 pharmaceuticals, in particular as modulators of toll-like receptor (especially TLR7) activity, and thus may be used in the treatment of:
• respiratory tract obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of alls severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and0 chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vascul
• skin psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber- Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis;cutaneous lymphomas, non-melanoma skin
• eyes blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; ulceris; anterior and posterior uveitis; choroiditis; autoimmune, degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral , fungal, and bacterial;
• nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvovaginitis; Peyronie's disease; erectile dysfunction (both male and female);
• allograft rejection acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or chronic graft versus host disease;
• oncology treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and, 8. infectious diseases: virus diseases such as genital warts, common warts, plantar
• hepatitis B hepatitis C
• herpes simplex virus molluscum contagiosum
• variola human immunodeficiency virus
• HPV human papilloma virus
• CMV cytomegalovirus
• VZV varicella zoster virus
• rhinovirus adenovirus, coronavirus, influenza, parainfluenza
• bacterial diseases such as tuberculosis and mycobacterium avium, leprosy
• other infectious diseases such as fungal diseases, chlamydia, Candida, aspergillus, cryptococcal io meningitis, Pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection and leishmaniasis.
• the present invention provides a compound of formula (I) or a pharmaceutically- acceptable salt thereof as hereinbefore defined for use in therapy.
• the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in therapy.
• the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary.
• the terms “therapeutic” and “therapeutically” should be construed accordingly.
• Prophylaxis is expected to be particularly relevant to the treatment of persons who have 2 5 suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question.
• Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
• the compounds of the invention may be used in the treatment of asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections and dermatosis.
• anti-cancer treatment may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy.
• chemotherapy may include one or more of the following categories of anti-tumour agents:- (i) other antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubi
• anti-invasion agents for example c-Src kinase family inhibitors like 4-(6-chloro-2,3- methylenedioxyanilino)-7-[2-(4-methylpiperazin-l-yl)ethoxy]-5-tetrahydropyran-4- yloxyquinazoline (AZD0530; International Patent Application WO 01/94341) and N-(2- chloro-6-methylphenyl)-2- ⁇ 6-[4-(2-hydroxyethyl)piperazin-l-yl]-2-methylpyrimidin-4- ylamino ⁇ thiazole-5-carboxamide (dasatinib, BMS-354825; J. Med. Chem..
• inhibitors of growth factor function include growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [HerceptinTM], the anti-EGFR antibody panitumumab, the anti-erbBl antibody cetuximab [Erbitux, C225] and any growth factor or growth factor receptor antibodies disclosed by Stern et al. Critical reviews in oncology/haematology, 2005, Vol. 54, pp 11-29); such inhibitors also include tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as
• N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZDl 839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3- morpholinopropoxy)-quinazolin-4-amine (CI 1033), erbB2 tyrosine kinase inhibitors such as lapatinib, inhibitors of the hepatocyte growth factor family, inhibitors of the platelet- derived growth factor family such as imatinib, inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for example sora
• antisense therapies for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;
• gene therapy approaches including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and
• immunotherapy approaches including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
• cytokines such as interleukin 2, interleukin 4 or granulocyte-ma
• the invention still further provides a method of treating, or reducing the risk of, an obstructive airways disease or condition (e.g. asthma or COPD) which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.
• an obstructive airways disease or condition e.g. asthma or COPD
• the daily dosage of the compound of the invention if inhaled, may be in the range from 0.05 micrograms per kilogram body weight ( ⁇ g/kg) to 100 micrograms per kilogram body weight ( ⁇ g/kg).
• the daily dosage of the compound of the invention may be in the range from 0.01 micrograms per kilogram body weight ( ⁇ g/kg) to 100 milligrams per kilogram body weight (mg/kg).
• the compounds of formula (I) and pharmaceutically acceptable salts thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
• a pharmaceutically acceptable adjuvant diluent or carrier.
• Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
• the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
• the present invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
• the invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier.
• compositions may be administered topically (e.g. to the skin or to the lung and/or airways) in the form, e.g., of creams, solutions, suspensions, heptafluoroalkane (HFA) aerosols and dry powder formulations, for example, formulations in the inhaler device known as the Turbuhaler ® ; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules; or by parenteral administration in the form of a sterile solution, suspension or emulsion for injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion); or by rectal administration in the form of suppositories.
• HFA heptafluoroalkane
• Dry powder formulations and pressurized HFA aerosols of the compounds of the invention may be administered by oral or nasal inhalation.
• the compound is desirably finely divided.
• the finely divided compound preferably has a mass median diameter of less than 10 micrometres ( ⁇ m), and may be suspended in a propellant mixture with the assistance of a dispersant, such as a C 8 - C 20 fatty acid or salt thereof, (for example, oleic acid), a bile salt, a phospholipid, an alkyl saccharide, a perfluorinated or polyethoxylated surfactant, or other pharmaceutically acceptable dispersant.
• a dispersant such as a C 8 - C 20 fatty acid or salt thereof, (for example, oleic acid), a bile salt, a phospholipid, an alkyl saccharide, a perfluorinated or polyethoxylated surfactant, or other pharmaceutically acceptable dispersant.
• the compounds of the invention may also be administered by means of a dry powder inhaler.
• the inhaler may be a single or a multi dose inhaler, and may be a breath actuated dry powder inhaler.
• a carrier substance for example, a mono-, di- or polysaccharide, a sugar alcohol, or another polyol.
• Suitable carriers are sugars, for example, lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol; and starch.
• the finely divided compound may be coated by another substance.
• the powder mixture may also be dispensed into hard gelatine capsules, each containing the desired dose of the active compound.
• This spheronized powder may be filled into the drug reservoir of a multidose inhaler, for example, that known as the Turbuhaler ® in which a dosing unit meters the desired dose which is then inhaled by the patient.
• a multidose inhaler for example, that known as the Turbuhaler ® in which a dosing unit meters the desired dose which is then inhaled by the patient.
• the active ingredient with or without a carrier substance, is delivered to the patient.
• the compound of the invention may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets.
• an adjuvant or a carrier for example, lactose, saccharose, sorbitol, mannitol
• a starch for example, potato starch, corn starch or amylopectin
• a cellulose derivative for example, gelatine or polyvinylpyrrolidone
• a lubricant for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax
• the cores may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide.
• a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide.
• the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent.
• the compound of the invention may be admixed with, for example, a vegetable oil or polyethylene glycol.
• Hard gelatine capsules may contain granules of the compound using either the above-mentioned excipients for tablets.
• liquid or semisolid formulations of the compound of the invention may be filled into hard gelatine capsules.
• Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol.
• Such liquid preparations may contain colouring agents, flavouring agents, saccharine and/or carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.
• the compounds of the invention may also be administered in conjunction with other compounds used for the treatment of the above conditions.
• the invention therefore further relates to combination therapies wherein a compound of the invention or a pharmaceutical composition or formulation comprising a compound of the invention is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.
• tumour necrosis factor alpha (TNF-alpha) inhibitors such as anti-TNF monoclonal antibodies (for example Remicade, CDP-870 and adalimumab) and TNF receptor immunoglobulin molecules (such as Enbrel); non-selective cyclo-oxygenase COX-l/COX-2 inhibitors whether applied topically or systemically (such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, azapropazone, pyrazolones such as phenylbutazone, salicylates such as aspirin), COX-2 inhibitors (such as meloxicam, celecoxicam, celecoxicam, celecoxicam, celecoxicam, celecoxicam, celecoxicam, celecoxicam, cele
• the present invention still further relates to the combination of a compound of the invention and a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5- lipoxygenase activating protein (FLAP) antagonist such as; zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; a N-(5-substituted)-thiophene-2- alkylsulfonamide; 2,6-di-tert-butylphenolhydrazones; a methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; a pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2-cyanoquinoline compound such as L-746,530; or an indole or quinoline compound such as MK-591, MK-886, and BAY x 1005.
• the present invention further relates to the combination of a compound of the invention and a receptor antagonist for leukotrienes (LT B4, LTC4, LTD4, and LTE4) selected from the group consisting of the phenothiazin-3-ls such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zaf ⁇ rlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.
• a receptor antagonist for leukotrienes selected from the group consisting of the phenothiazin-3-ls such as L-651,392; amidino compounds such as CGS-25019c; benzoxal
• the present invention still further relates to the combination of a compound of the invention and a phosphodiesterase (PDE) inhibitor such as a methylxanthanine including theophylline and aminophylline; a selective PDE isoenzyme inhibitor including a PDE4 inhibitor an inhibitor of the isoform PDE4D, or an inhibitor of PDE5.
• PDE phosphodiesterase
• the present invention further relates to the combination of a compound of the invention and a histamine type 1 receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine; applied orally, topically or parenterally.
• a histamine type 1 receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine
• the present invention still further relates to the combination of a compound of the invention and a gastroprotective histamine type 2 receptor antagonist.
• the present invention further relates to the combination of a compound of the invention and an antagonist of the histamine type 4 receptor.
• the present invention still further relates to the combination of a compound of the invention and an alpha- l/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, tramazoline hydrochloride or ethylnorepinephrine hydrochloride.
• an alpha- l/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochlor
• the present invention further relates to the combination of a compound of the invention and an anticholinergic agent including muscarinic receptor (Ml, M2, and M3) antagonists such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine.
• Ml, M2, and M3 antagonists such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine.
• the present invention still further relates to the combination of a compound of the invention together with a beta-adrenoceptor agonist (including beta receptor subtypes 1-4) such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol.
• a beta-adrenoceptor agonist including beta receptor subtypes 1-4
• beta receptor subtypes 1-4 such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol.
• the present invention further relates to the combination of a compound of the invention and a chromone, such as sodium cromoglycate or nedocromil sodium.
• a chromone such as sodium cromoglycate or nedocromil sodium.
• the present invention still further relates to the combination of a compound of the invention together with an insulin-like growth factor type I (IGF-I) mimetic.
• IGF-I insulin-like growth factor type I
• the present invention still further relates to the combination of a compound of the invention and a glucocorticoid, such as flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate.
• the present invention still further relates to the combination of a compound of the invention together with an inhibitor of matrix metalloproteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-I), collagenase-2 (MMP-8), collagenase-3 (MMP- 13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) and MMP-9 and MMP- 12.
• MMPs matrix metalloproteases
• the present invention still further relates to the combination of a compound of the invention together with modulators of chemokine receptor function such as antagonists of CCRl, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCRl 1 (for the C-C family); CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX3CR1 for the C-X3-C family.
• modulators of chemokine receptor function such as antagonists of CCRl, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCRl 1 (for the C-C family); CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX3CR1 for the C-X
• the present invention still further relates to the combination of a compound of the invention together with a cytokine or modulator of cytokine function, including alpha-, beta-, and gamma-interferon; interleukins (IL) including ILl to 15, and interleukin antagonists or inhibitors, including agents which act on cytokine signalling pathways.
• a cytokine or modulator of cytokine function including alpha-, beta-, and gamma-interferon
• interleukins (IL) including ILl to 15
• interleukin antagonists or inhibitors including agents which act on cytokine signalling pathways.
• the present invention still further relates to the combination of a compound of the invention together with an immunoglobulin (Ig) or Ig preparation or an antagonist or antibody modulating Ig function such as anti-IgE (omalizumab).
• Ig immunoglobulin
• Ig preparation or an antagonist or antibody modulating Ig function such as anti-IgE (omalizumab).
• the present invention further relates to the combination of a compound of the invention and another systemic or topically-applied anti-inflammatory agent, such as thalidomide or a derivative thereof, a retinoid, dithranol or calcipotriol.
• the present invention further relates to the combination of a compound of the invention together with an antibacterial agent such as a penicillin derivative, a tetracycline, a macrolide, a beta-lactam, a fluoroquinolone, metronidazole, an inhaled aminoglycoside; an antiviral agent including acyclovir, famciclovir, valaciclovir, ganciclovir, cidofovir, amantadine, rimantadine, ribavirin, zanamavir and oseltamavir; a protease inhibitor such as indinavir, nelfinavir, ritonavir, and saquinavir; a nu
• a compound of the invention can also be used in combination with an existing therapeutic agent for the treatment of cancer, for example suitable agents include: (i) an antiproliferative/antineoplastic drug or a combination thereof, as used in medical oncology, such as an alkylating agent (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan or a nitrosourea); an antimetabolite (for example an antifolate such as a fluoropyrimidine like 5-fluorouracil or tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine or paclitaxel); an antitumour antibiotic (for example an anthracycline such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dact
• a cytostatic agent such as an antioestrogen (for example tamoxifen, toremifene, raloxifene, droloxifene or iodoxyfene), an oestrogen receptor down regulator (for example fulvestrant), an antiandrogen (for example bicalutamide, flutamide, nilutamide or cyproterone acetate), a LHRH antagonist or LHRH agonist (for example goserelin, leuprorelin or buserelin), a progestogen (for example megestrol acetate), an aromatase inhibitor (for example as anastrozole, letrozole, vorazole or exemestane) or an inhibitor of 5 ⁇ -reductase such as finasteride; (iii) an agent which inhibits cancer cell invasion (for example a metalloproteinase inhibitor like marimastat or an inhibitor of urokinase plasm
• an antiangiogenic agent such as one which inhibits the effects of vascular endothelial growth factor (for example the anti- vascular endothelial cell growth factor antibody bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or WO 98/13354), or a compound that works by another mechanism (for example linomide, an inhibitor of integrin ⁇ v ⁇ 3 function or an angiostatin);
• vascular endothelial growth factor for example the anti- vascular endothelial cell growth factor antibody bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or WO 98/13354
• a compound that works by another mechanism for example linomide, an inhibitor of integrin ⁇ v ⁇ 3 function or an angiostatin
• a vascular damaging agent such as combretastatin A4, or a compound disclosed in WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 or WO 02/08213;
• an agent used in antisense therapy for example one directed to one of the targets listed above, such as ISIS 2503, an anti-ras antisense;
• an agent used in a gene therapy approach for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; or
• an agent used in an immunotherapeutic approach for example ex-vivo and in- vivo approaches to increase the
• step (ii) 2-Butoxy-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine
• the product from step (i) (4Og) was dissolved in 19%(w/w)-sodium butoxide in butanol (250ml).
• the reaction mixture was stirred under reflux for 6h.
• the resultant suspension was cooled to rt, diluted with water and extracted with diethyl ether.
• the combined organic phase was washed with water, dried and concentrated in vacuo.
• the subtitle compound was crystallised from diethyl ether/isohexane (1/1, 300ml) and obtained by filtration. Yield 19g.
• step (ii) (30g) was dissolved in dry dichloromethane (200ml). The solution was stirred at rt whilst NBS (27g) was added portionwise. The mixture was stirred at rt overnight. 20%(w/v)-Sodium sulfate (200ml) was added and the separated aqueous phase extracted with DCM. The combined organic phase was washed with saturated sodium hydrogen carbonate solution and brine. After concentration in vacuo, the residue was dissolved in ethyl acetate, washed with water, brine and dried. The solution was filtered through silica gel and concentrated in vacuo.
• step (iv) 24g was dissolved in absolute MeOH (300ml) and 30ml of TFA was added. The reaction mixture was stirred at it for 3 days and concentrated in vacuo. The subtitle compound was obtained as a white crystalline solid after trituration with MeOH /ethyl acetate. Yield 2 Ig.
• step (v) 50g was added in portions over 10 minutes to a rapidly stirred mixture of potassium carbonate (6Og) and l-bromo-3-chloropropane (21ml) in DMF (400ml) at rt and the mixture stirred for 3h. The mixture was diluted with water and extracted with ethyl acetate. The combined extracts were washed with water and dried. The crude product was recrystallised from acetonitrile. Yield 29.83g. MS:ESI (+ve): 314
• step (vii) 6-Amino-9-(3-chloropropyl)-2-butoxy-7,9-dihydro-8H-purin-8-one
• step (vi) 29.8g
• MeOH 60ml
• 4M hydrogen chloride 40ml
• dioxane 60ml
• the mixture was stirred at rt for 2 hours, cooled to 0°C and neutralised with 3.5% aqueous ammonia solution.
• the solid was filtered off, washed with water then MeOH and dried Yield 27.2g.
• step (viii) 6- Amino-2-butoxy-9-(3 -pyrrolidin- 1 -ylpropyl)-7,9-dihydro-8H-purin-8-one
• DMSO dimethyl sulfoxide
• Examples 2-4 were made by the same method as example 1 using the appropriate amine:
• Example 3 is 6-Amino-2-butoxy-9- ⁇ 3-[(2S)-2-(methoxymethyl)pyrrolidin-l-yl]propyl ⁇ -7,9-dihydro- 8H-purin-8-one
• Human TLR7 assay Recombinant human TLR7 was stably expressed in a HEK293 cell line already stably expressing the pNiFty2-SEAP reporter plasmid; integration of the reporter gene was maintained by selection with the antibiotic zeocin. The most common variant sequence of human TLR7 (represented by the EMBL sequence AF240467) was cloned into the mammalian cell expression vector pUNO and transfected into this reporter cell-line.
• Transfectants with stable expression were selected using the antibiotic blasticidin.
• expression of secreted alkaline phosphatase (SEAP) is controlled by an NFkB/ELAM-1 composite promoter comprising five NFkB sites combined with the proximal ELAM-I promoter.
• TLR signaling leads to the translocation of NFkB and activation of the promoter results in expression of the SEAP gene.
• TLR7-specific activation was assessed by determining the level of SEAP produced following overnight incubation of the cells at 37°C with the standard compound in the presence of 0.1% (v/v) dimethylsulfoxide (DMSO). Concentration dependent induction of SEAP production by compounds was expressed as the concentration of compound which produced half of the maximal level of SEAP induction for that compound (pEC 50 ).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Virology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Pulmonology (AREA)
• Molecular Biology (AREA)
• Immunology (AREA)
• Biotechnology (AREA)
• AIDS & HIV (AREA)
• Tropical Medicine & Parasitology (AREA)
• Ophthalmology & Optometry (AREA)
• Dermatology (AREA)
• Otolaryngology (AREA)
• Gastroenterology & Hepatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=39529746

Family Applications (1)

Country Status (9)

Cited By (51)

Families Citing this family (17)

Citations (4)

Family Cites Families (72)

• 2008
  • 2008-03-19 ES ES08718797.7T patent/ES2457316T3/es active Active
  • 2008-03-19 JP JP2009554081A patent/JP5480637B2/ja active Active
  • 2008-03-19 DK DK08718797.7T patent/DK2132209T3/da active
  • 2008-03-19 US US12/532,090 patent/US8067413B2/en active Active
  • 2008-03-19 EP EP08718797.7A patent/EP2132209B8/en active Active
  • 2008-03-19 PT PT87187977T patent/PT2132209E/pt unknown
  • 2008-03-19 WO PCT/GB2008/000958 patent/WO2008114008A1/en active Application Filing
  • 2008-03-19 SI SI200831181T patent/SI2132209T1/sl unknown
• 2014
  • 2014-04-15 CY CY20141100284T patent/CY1115175T1/el unknown

Patent Citations (4)

Also Published As

Similar Documents

Legal Events